The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...
Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...
Hosted on MSN1d
Supernus’s stock sinks after depression drug fails trialSupernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...
Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
All three doses hit the trial’s primary endpoint of demonstrating ... upfront for the license to Anaptys’ phase 3-stage pustular psoriasis drug imsidolimab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback